TREAT-1: EL219 versus liposomal amphotericin B or voriconazole for early antifungal therapy of invasive mould infections

Phase 2, randomised, double-blind trial of turletricin in Invasive mold disease (IMD) (3 arms), sponsored by Elion Therapeutics. Primary endpoints: All-cause mortality at Day 21 and Serious adverse events and treatment-emergent adverse events during blinded treatment. Planned start May 2026; status: authorised.